Background: We previously reported that N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) treatment caused large increases of ceramide levels in neuroblastoma cell lines and induced cell death by a combination of apoptosis and necrosis through p53 (also known as TP53)-independent and caspase-independent pathways. Our goal was to determine if several molecules that inhibit enzymes involved in ceramide metabolism-L-threo-dihydrosphingosine ( 
The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is cytotoxic to a variety of cancer cell lines (1) (2) (3) (4) (5) (6) (7) . One reported mechanism of 4-HPR cytotoxicity involves generation of reactive oxygen species (ROS) (8, 9) , and 4-HPR cytotoxicity is associated with c-Jun N-terminal kinase (JNK) activation in PC-3 prostate carcinoma cells (10) . Recently, we (11) reported that 4-HPR substantially increased ceramide in neuroblastoma cells and induced cell death in a p53-and caspase-independent manner by mixed apoptosis and necrosis pathways.
Ceramide, generated in separate cellular compartments by de novo synthesis or sphingomyelin breakdown, can increase ROS, promote apoptosis or necrosis, including p53-independent apoptosis under hypoxic conditions, activate pro-death JNK/stressactivated protein kinase (JNK/SAPK) in a manner opposed by sphingosine-1-phosphate activation of extracellular signalregulated kinases (ERK1/2), and may induce Bcl2 dephosphorylation (12) (13) (14) (15) . Ceramide can be metabolized to less toxic forms by glucosylation via glucosylceramide synthase (16) and by acylation via 1-O-acylceramide synthase (17) . The cytotoxicity of exogenous ceramide and sphingomyelinase is potentiated by sphingoid bases (18) and by inhibitors of ceramide glycosylation (19) and opposed by ceramide activation of protein kinase C zeta (PKC-) (20) , possibly by stimulating sphingosine kinase activity (21) , by increasing NF-kappaB (12, 22) , or by other mechanisms (23, 24) . A schematic of the pathways of ceramide synthesis and relevant enzymes is shown in Fig. 1 .
We have determined the mechanism of 4-HPR-induced ceramide generation and whether putative modulators of ceramiderelated pathways can increase 4-HPR cytotoxicity. Specifically, we examined the effects on 4-HPR-mediated cytotoxicity and ceramide generation of L-threo-dihydrosphingosine (safingol), which is an atypical protein kinase C inhibitor (25) (26) (27) , and d,l-threo-1-phenyl-2-hexadecanoylamino-3-morpholino-1-propanol (PPMP) and tamoxifen, which are inhibitors of glucosylceramide synthase/1-O-acylceramide synthase (28) (29) (30) .
Cell Culture
The human neuroblastoma cell lines CHLA-79 (31) , , and CHLA-171 (32) were established from a relapsed tumor in bone marrow after myeloablative chemoradiotherapy supported by autologous bone marrow transplant (CHLA-79 and CHLA-90) or from a relapsed tumor following treatment with buthionine sulfoximine (BSO) plus melphalan (CHLA-171) and were maintained in IMDM supplemented with 0.7 mM L-glutamate, insulin, and transferrin (5 g/mL each), selenium (5 ng/mL), and 20% heat-inactivated FBS (complete IMDM). Cultures of normal human fibroblasts CRL-2076 and CRL-2091 were maintained in complete IMDM. Pancreatic cancer cell lines PANC-1 and Hs 766T were maintained in Dulbecco's modified Eagle medium High Glucose medium and 10% heat-inactivated FBS. The colon cancer cell line LoVo, the prostate cancer cell line PC-3, and the lung carcinoma cell line A-549 were maintained in Ham's F-12K medium with 10% heat-inactivated FBS and 2 mM glutamate. Other neuroblastoma (31, 33, 34) and non-neuroblastoma human cell lines were maintained in RPMI-1640 medium supplemented with 10% heatinactivated FBS without antibiotics (complete medium). Other nonneuroblastoma cell lines were purchased from the American Type Culture Collection, Manassas, VA, except DoxR MCF7, a doxorubicin-resistant MCF-7 breast cancer cell line derivative (35) , which was a gift from Drs. Kenneth Cowan and Merrill Goldsmith (National Cancer Institute, Bethesda, MD), and the MCF-7/tet cell line, which is MCF-7 transfected with a doxycyclinecontrolled reverse Tet repressor construct (36) . Cell lines were cultured at 37°C in a humidified incubator in an atmosphere of 95% room air plus 5% CO 2 . Neuroblastoma cells were detached without trypsin from culture plates with the use of a modified Puck's solution A plus EDTA (Puck's EDTA) that contains 140 mM NaCl, 5 mM KCl, 5.5 mM glucose, 4 mM NaHCO 3 , 0.8 mM EDTA, 13 M Phenol Red, and 9 mM HEPES buffer (pH 7.3) (34) . Non-neuroblastoma cells were detached with Puck's EDTA plus 0.25% trypsin.
For cytotoxicity assays (described below) in reduced oxygen conditions, cells were prepared and treated with drugs as described previously (11) . Under these conditions, medium in microplate wells attains a pO 2 below the degree of hypoxia found in bone marrow (37) and in the range of hypoxia found in tumor tissue (38) .
Cytotoxicity Assay
Cytotoxicity in cell lines was determined with the use of a fluorescence-based assay employing digital imaging microscopy (DIMSCAN) (11) . DIMSCAN quantitates viable cells that selectively accumulate fluorescein diacetate and is capable of measuring cytotoxicity over a 4-to 5-log dynamic range by quantifying total fluorescence per well (which is proportional to viable, clonogenic cells) after eliminating background fluorescence with the use of digital thresholding and eosin Y quenching. Cell lines were seeded into 96-well plates in 100 L of complete medium per well as described previously (11) . Cells were allowed to attach overnight prior to the addition of drugs in 50-L volumes of complete medium to various final drug concentrations in replicates of 12 wells per concentration. The effects of fumonisin B 1 on cytotoxicity were assessed by preincubation of the cells with 90 M fumonisin B 1 for 16 hours before the addition of other drugs. The effects of L-cycloserine on cytotoxicity were assessed by preincubation of the cells with 2 mM L-cycloserine for 3 hours before the addition of other drugs. Control wells received ethanol (final concentration ‫ס‬ 0.12%-0.20%) in complete medium equivalent to the maximum final ethanol concentration of drug-treated wells. Plates were assayed 4-7 days after the initiation of drug exposure, depending on the growth properties of each cell line, to allow for maximum cell death and outgrowth of surviving cells. To measure cytotoxicity, we added fluorescein diacetate (stock solution of 1 mg/mL in dimethyl sulfoxide) in 50 L of complete medium per well, to a final concentration of 10 g/mL. The plates were incubated for an additional 15-30 minutes at 37°C, and then 30 L of eosin Y (0.5% in normal saline) was added per well. The total fluorescence of each well was then measured with the use of DIMSCAN as described previously (39) . For L-cycloserine treatment in the MCF-7/tet cell line, the cytotoxic effects of 4-HPR and 4-HPR/safingol are expressed as the increase in cytotoxicity above that produced by treatment with L-cycloserine alone; i.e., cytotoxic results are normalized for the cytotoxicity found in controls treated with only L-cycloserine.
The results were analyzed and expressed as survival fractions by a comparison of the quantified fluorescence of surviving cells to that of control cells with the use of Microsoft Excel 97© software (Microsoft Corp., Redmond, WA) and were graphed with the use of SigmaPlot 5.0 (Jandell Scientific, San Rafael, CA). The limits of detection were determined by the estimated number of cells present in control wells at the time that they were treated with drug, generally targeted at 10 × 10 3 cells, for a detection limit for cytotoxicity of one live cell at the end of the assay per 10 000 starting cells. For many cell lines, the presence of more than 10 × 10 3 cells on day +0 resulted in overgrowth of the control wells by the day of assay, although for slower growing cell lines, such as SMS-LHN, a greater detection limit was possible. For simplicity, all results are graphed with a detection limit of 10 −4 . The stability of 4-HPR, safingol, PPMP, L-cycloserine, tamoxifen, and fumonisin B 1 for 4-7 days in the DIMSCAN cytotoxicity assay system is not known.
The cytotoxicity of drugs to human bone marrow myeloid (granulocytes and 6 ) were resuspended in 5 mL of IMDM plus 20% FBS medium in replicate T25 flasks, drug or ethanol (controls) was added to final concentrations, and flasks were incubated at 37°C in humidified 20% oxygen plus 5% CO 2 (day 0). At 24-hour intervals, the flasks were agitated, and 1 mL of medium was removed. The cells were harvested by centrifugation at 375g for 3 minutes at room temperature and resuspended in 1 mL of IMDM with 10% human serum albumin. An aliquot (0.4 mL) of resuspended cells was mixed with 0.2 mL of 8 × 10 3 g/mL of GM-CSF and 3.4 mL of the following agar mix: 1.2× Iscove's medium, 0.5% bacto agar, 20% fetal calf serum, 1.6 mM L-glutamine, 100 U/mL penicillin/streptomycin, and 0.9 M ␣-thioglycerol at approximately 50°C. Aliquots (1 mL) of the cell-agar mix were plated in 35 × 10-mm tissue culture dishes in triplicate and incubated for 12 days at 37°C in humidified 20% oxygen plus 5% CO 2 . Colonies of 50 cells or more were scored, and the results were expressed as colonies per 2 × 10 5 cells of the initial cell inoculum placed in the flask on day 0.
Lipid Analysis
Methods were described previously (11) . Briefly, tritium-labeled lipids were prepared by [ 3 H]palmitic acid exposure of cultured cells. Total cellular lipids were extracted as described previously (11) . Commercial lipid standards (5 g/lane) were co-spotted onto TLC plates with the cellular 3 H-labeled lipids (10-L aliquots). Ceramide was resolved in a solvent system containing chloroform/acetic acid (90 : 10, vol/vol). Glucosylceramide was resolved in a solvent system containing chloroform/methanol/ammonium hydroxide (70 : 20 : 4, vol/ vol). The lipid standards were visualized by iodine vapor, and we assayed the comigrating tritiated lipid sample by scraping the TLC plate in the area of interest, adding 0.5 mL water and 4.5 mL of Ecolume scintillation cocktail, vortexing, and measuring the counts per minute of tritium by liquid scintillation counting. This value was then corrected for the amount of the original sample previously removed for other assays. Lipid changes are expressed as the mean -fold increase or decrease in three drug-treated samples as compared with that of three matched controls. For some assays, a sphinganine N-acyltransferase (dihydroceramide synthase) inhibitor (40) , fumonisin B 1 , was added to 90 M at 16 hours before the addition of other drugs, or a serine palmitoyltransferase inhibitor (41), L-cycloserine, was added to 2 mM 3 hours before the addition of other drugs. Drugs did not affect [ 3 H]palmitic acid uptake. The ceramide isolated by the above assay method has been verified by mass spectroscopy to contain only ceramide species.
Statistical Analysis
Cytotoxicity and lipid data are presented as means ± 95% confidence intervals. The 95% confidence interval was calculated as 1.96/√n, where ‫ס‬ the standard deviation of ungrouped data and n ‫ס‬ the number of trials. The statistical significance of differences in means was evaluated by the unpaired, twosided Student's t test with the use of Microsoft© Excel 97 software. All P values are two-sided.
Drug-induced cytotoxic synergy was analyzed and graphed with the use of CalcuSyn software from Biosoft, Cambridge, U.K. and was expressed as the combination index at the LC 99 (i.e., concentration lethal to 99% of cells) (42) . The combination index is a method for quantifying drug cytotoxic synergism, based on the Mass-Action Law approach and the Median-Effect Principle derived from enzyme kinetic models as developed by Chou and Talalay, which has been widely used to evaluate interactions of antineoplastic drugs (43) . With the use of the combination index, synergism is defined as a more than expected additive effect, and antagonism is defined as a less than expected additive effect. By this method, a combination index equal to 1 indicates an additive effect, a combination index less than 1 indicates synergy, and a combination index greater than 1 indicates antagonism. With the use of CalcuSyn software, synergy is further refined as synergism (combination index ‫ס‬ 0.3-0.7), strong synergism (combination index ‫ס‬ 0.1-0.3), and very strong synergism (combination index <0.1) (42). The combination index (CIN) value can be calculated at different "effect levels" or "fraction affected" levels (e.g., LC 50 [i.e., concentration lethal to 50% of the cells] or LC 99 ) and may vary depending on the fractional effect level at which it is calculated. The mutually nonexclusive assumption was used in these analyses. For combination index plots, the combination index is plotted as the log 10 (CIN) versus fraction affected (defined as 1 -survival fraction), and the 95% confidence intervals are shown where calculable, with the use of the algebraic approximation method of the CalcuSyn program. On these plots, additivity is, therefore, defined as log 10 (CIN) ‫ס‬ 0; very strong synergy is defined as log 10 (CIN) ‫ס‬ −1; and antagonism is defined as log 10 (CIN) >0. Note: While synergism and cytotoxicity may be related, a combination index indicating strong synergy does not necessarily imply a high degree of absolute cytotoxicity (i.e., a small survival fraction); conversely, a combination index indicating antagonism need not exclude a high degree of cytotoxicity.
All results were experimentally reproducible.
RESULTS

Effect of Safingol on 4-HPR Cytotoxicity in Tumor Cell Lines
Safingol ( Table 1 ). Safingol plus 4-HPR (4-HPR/safingol) synergized and/or caused multilog cell killing in four lung cancer cell lines ( Fig. 2 99 , combination index value range ‫ס‬ 0.2-0.5). 4-HPR/safingol retained multilog cytotoxicity (P<.001) compared with controls in the SMS-LHN (Fig. 4, A) and CHLA-90 (data not shown) neuroblastoma cell lines, when assayed in 2.5% oxygen. Conditions of reduced oxygen have been shown previously to reduce 4-HPR singleagent cytotoxicity in these cell lines (11) .
Effect of Safingol on 4-HPR Cytotoxicity in Normal Fibroblasts and Marrow GM-CFU
4-HPR/safingol was minimally cytotoxic to CRL-2076 normal human fibroblasts (Fig. 4, B) . The addition of safingol (4 M) did not affect the cytotoxicity of 4-HPR (12 M) (P ‫ס‬ .32), but safingol (ജ6 M) increased the cytotoxicity (P<.001) at +96 hours. Similar results were observed in CRL-2091 normal human fibroblasts (data not shown). 4-HPR/safingol (9 M/3 M) did not cause significant cytotoxicity to bone marrow myeloid progenitors (GM-CFU) at +72 hours (P ‫ס‬ .89; Fig. 4 , C) compared with control cells.
Effects of 4-HPR and Inhibitors of De Novo Ceramide Synthesis on Ceramide Levels
As reported previously (11), 4-HPR (10 M) progressively increased radiolabeled ceramide levels fourfold to fivefold at +24 hours in CHLA-90 neuroblastoma cells (Fig. 5, B (11) . To determine the synthetic route of the ceramide increased by 4-HPR in CHLA-90 cells, we assayed the effects of two inhibitors of de novo ceramide synthesis. L-Cycloserine (2 mM) (44) is an inhibitor of serine palmitoyltransferase, the initial and rate-limiting step of de novo ceramide synthesis (45) . Fumonisin B 1 (90 M), is an inhibitor of (dihydro)ceramide synthase (40) . Both inhibitors prevented (P<.001) 4-HPR-induced ceramide increases at +6 hours (Fig. 5, A) . Neither drug affected the cellular uptake of [ 3 H]palmitic acid (data not shown). The effect of more prolonged exposure of L-cycloserine on ceramide increase could not be ascertained because it proved to be too cytotoxic at +24 hours in CHLA-90 cells (not shown). However, fumonisin B 1 prevented ceramide increases at +24 hours (P ‫ס‬ .002) and at +48 hours (P<.001) (Fig. 5, B) . Together, these results strongly suggest that the 4-HPR-mediated ceramide increase was from de novo synthesis, although these data do not exclude the possibility that 4-HPR might also increase ceramide levels by decreasing its degradation into sphingosine or its conversion into sphingomyelin or glucosylceramides. However, in CHLA-90 and SMS-LHN neuroblastoma cells, 4-HPR (10 M) increased tritium-labeled glucosylceramide levels approximately 3.8-fold (P<.001) and approximately 2.5-fold (P ‫ס‬ .003) and sphingomyelin levels approximately threefold (P ‫ס‬ .06) and approximately 2.8-fold (P ‫ס‬ .006), respectively, over controls at +24 hours, indicating that neither glucosylceramide synthase nor sphingomyelin synthesis was inhibited by 4-HPR (right panel of Fig. 6 , A, and data not shown).
Significantly, in CRL-2076 normal fibroblasts, 4-HPR only increased ceramide levels by approximately 50% (P ‫ס‬ .03) at +24 hours (Fig. 5, D) .
Safingol Incorporated Into a Stereochemical Variant of Ceramide (cer*)
Safingol, the L-threo-isomer of native sphinganine (D-erythro-dihydrosphingosine) (Fig. 1) has been reported to be incorporated into a stereochemically variant ceramide (here termed "cer*") via acylation by (dihydro)ceramide synthase in rat liver in vivo (46, 47) . To confirm this, we assayed for ceramide species after safingol exposure and determined the effects of L-cycloserine (2 mM) and fumonisin B 1 (90 M) on levels of ceramide species. No drug affected the cellular uptake of [ 3 H]palmitic acid (data not shown). Safingol (3 M) increased the level of a ceramide species (cer*) ninefold at +6 hours (P ‫ס‬ .002) (Fig. 5, A) and approximately 17-fold at +24 hours (P ‫ס‬ .004) (Fig. 5, C) in CHLA-90 cells; however, significantly, glucosylceramide levels remained unchanged at +24 hours (P ‫ס‬ .84) (Fig. 5, C) . The increase in ceramide species (cer*) was unaffected by L-cycloserine at +6 hours (P ‫ס‬ .8) but was blocked completely by fumonisin B 1 (P ‫ס‬ .002) (Fig. 5, A) ; taken together, these findings strongly suggest that radiolabeling was via acylation of tritiated palmitoyl-coenzyme A by (dihydro)ceramide synthase into an abundant dihydrosphingosine species that was not derived from de novo synthesis (i.e., safingol). Thus, the ceramide species increased by safingol probably represented acylated-safingol (cer*), the L-threo-stereochemical analogue of native ceramide (D-erythro-N-acylsphingosine). The accompanying lack of an increase in glucosylceramide levels (Fig. 5, C) suggests that cer* is not readily glucosylated by glucosylceramide synthase, unlike the ceramide induced by 4-HPR (P<.001) ( Fig. 5, C ; right panel of Fig. 6, A) . Combining safingol with 4-HPR (4-HPR/safingol) produced an apparent additive increase in total ceramide species (P ‫ס‬ .12) (Fig. 5, C) at +24 hours compared with safingol alone, presumably representing the summed production of native ceramide induced by 4-HPR and of safingol-derived, cer* (indistinguishable by this assay method). Glucosylceramide levels increased (P ‫ס‬ .09) (Fig 5, C) with 4-HPR/safingol only to the same extent (P ‫ס‬ .73) as with 4-HPR alone (Fig. 5, C) , again suggesting that cer* cannot be glycosylated by glucosylceramide synthase. Metastatic *MCYN, amp ‫ס‬ genomic amplification of MCYN. PD-BMT ‫ס‬ progressive disease after myeloablative chemotherapy supported by bone marrow transplantation; PD-BSO/L-PAM ‫ס‬ progressive disease after buthionine sulfoxamine/ melphalan treatment; PD-Ind ‫ס‬ progressive disease after induction chemotherapy; SCLC ‫ס‬ small-cell lung carcinoma; ↑c-myc ‫ס‬ increased expression of c-myc messenger RNA; p53 wt ‫ס‬ wild-type p53 protein expression; p53 null ‫ס‬ absent p53 protein expression; p53 mut ‫ס‬ expression of mutated p53 protein; caspase-3 mut ‫ס‬ mutated caspase 3 gene. Fig. 2 (see facing page) . L-Cycloserine only somewhat decreased the total ceramide species increase induced by 4-HPR/safingol (P ‫ס‬ .07) (Fig. 5, A) , presumably reflecting the decrease in the smaller amount of native ceramide induced by 4-HPR, without an effect on the greater incorporation of safingol into cer*. Fumonisin B 1 prevented the ceramide species increase induced by 4-HPR/safingol (P ‫ס‬ .004) (Fig. 5, A) , consistent with the interpretation that inhibiting (dihydro)ceramide synthase prevents both the increase in native ceramide levels induced by 4-HPR via de novo synthesis and the incorporation of safingol into cer*. It is interesting that, in the 4-HPR-resistant SK-N-RA cell line (Fig. 2, A) , 4-HPR (10 M) increased ceramide levels only approximately 3.5-fold (P ‫ס‬ .004) and safingol (3 M) increased cer* levels only approximately sixfold (P ‫ס‬ .001) at +24 hours (data not shown), suggesting that decreased production or increased degradation of ceramide and cer* may occur in this cell line. Since 4-HPR-induced ceramide levels increased in a time-dependent manner (11), the cumulative effects of decreased production or increased degradation may account for the decreased 4-HPR sensitivity of this cell line compared with other neuroblastoma cell lines when cytotoxicity was assayed at +5 days (see the "Methods" section). Of the cell lines tested, 4-HPR/safingolinsensitive normal fibroblasts (Fig. 4, B) demonstrated the least increase in 4-HPR-stimulated ceramide levels, an approximately 50% increase (P ‫ס‬ .03) at +24 hours (Fig. 5, D) , safingol only increased the levels of cer* approximately 4.5-fold (P<.001) (Fig. 5, D) , and 4-HPR/safingol did not increase the levels of ceramide species compared with safingol alone (P ‫ס‬ .38) (Fig.  5, D) , further suggesting a relationship between induced ceramide levels and 4-HPR and 4-HPR/safingol sensitivity.
Effects of Glucosylceramide Synthase Inhibitors
Glucosylceramide synthase converts ceramide into nontoxic glucosylceramide (Fig. 1) . Overexpression of glucosylceramide synthase decreases ceramide levels and increases cellular resistance after doxorubicin exposure (36) . At +24 hours, 4-HPR (10 M) increased ceramide levels in CHLA-90 cells approximately 5.5-fold (P ‫ס‬ .002) and glucosylceramide levels approximately 3.5-fold (P ‫ס‬ .01) (right panel of Fig. 6, A) . The glucosylceramide synthase/1-O-acylceramide transferase inhibitor PPMP (28,48) at 6 M reduced glucosylceramide formation (P ‫ס‬ .009) below control levels (P ‫ס‬ .01) and increased ceramide levels (P ‫ס‬ .05) compared with 4-HPR alone at +24 hours in CHLA-90 cells (right panel of Fig 6, A) , whereas 2 M tamoxifen-a weaker, less specific glucosylceramide synthase inhibitor (30,49)-reduced glucosylceramide levels (P ‫ס‬ .02) to a lesser extent and did not increase ceramide levels (P ‫ס‬ .52) (right panel of . 3 (see facing page) (Fig. 6, D) ; however, safingol/tamoxifen (1 : 1 ratio) (4 M) slightly increased 4-HPR (12 M) cytotoxicity in an additive manner at +96 hours (survival fraction ‫ס‬ 0.78 versus 0.64; P<.001; LC 99 , combination index value ‫ס‬ 1.0) (Fig. 6, D) . Similar results were observed in CRL-2076 normal human fibroblasts (data not shown).
. Effects of L-threo-dihydrosphingosine (safingol) on N-(4-hydroxyphenyl)retinamide (4-HPR) cytotoxicity in various solid tumor cell lines. A) Dose response of melanoma cell lines to 4-HPR (H), safingol (S), and 4-HPR/safingol (3 : 1 molar ratio) (H+S) with the use of a fluorescence-based assay employing digital imaging microscopy (DIMSCAN). B) Dose response of prostate cancer cell lines to 4-HPR (H), safingol (S), and 4-HPR/safingol (3 : 1 molar ratio) (H+S) assayed by DIMSCAN. C) Dose response of colon cancer cell lines to 4-HPR (H), safingol (S), and 4-HPR/safingol (3 : 1 molar ratio) (H+S) assayed by DIMSCAN. D) Dose response of breast cancer cell lines to 4-HPR (H), safingol (S), and 4-HPR/safingol (3 : 1 molar ratio) (H+S) assayed by DIMSCAN. E) Dose response of colon cancer cell lines to 4-HPR (H), safingol (S), and 4-HPR
Effects of Inhibitors of De Novo Ceramide Synthesis on Cytotoxicity
To directly demonstrate the extent to which de novo ceramide production contributed to 4-HPR and 4-HPR/safingol cytotoxicity, we attempted to determine the effects of inhibitors of de novo ceramide synthesis on cytotoxicity. However, prolonged exposures (>16 hours) to L-cycloserine or ␤-chloro-L-alanine, inhibitors of serine palmitoyltransferase, the rate-limiting step of ceramide synthesis (41), proved to be too cytotoxic in the neuroblastoma cell lines tested to be used for this purpose (data not shown) (50) . Prolonged L-cycloserine exposure (>16 hours) was also cytotoxic (P<.001) to an MCF-7 breast cancer cell line derivative compared with ethanol-only-exposed controls (Fig. 7,  A) , although to a lesser extent than in neuroblastoma cell lines. Within this limitation, normalized to L-cycloserine-treated controls, L-cycloserine (2 mM) significantly reduced the increase in cytotoxicity of 4-HPR (P<.001) and of 4-HPR/safingol (P<.001 at 6 M: 2 M; P ‫ס‬ .02 at 9 M: 3 M) observed in this cell line compared with 4-HPR and 4-HPR/safingol treatment alone (Fig. 7, A) . Paradoxically, fumonisin B 1 , an inhibitor of ceramide synthase, slightly increased the cytotoxicity of 4-HPR in CHLA-90 cells (P<.01 at 3 M; P ‫ס‬ .01 at 6 M; P<.001 at Fig. 7, B) , likely because of the accumulation of the cytotoxic sphingolipids sphinganine and sphingosine, resulting from fumonisin B 1 exposure (51, 52 ). An interpretation of the effect of fumonisin B 1 on 4-HPR/safingol cytotoxicity in these cell lines was less clear (left and right panels of Fig. 7, B) .
DISCUSSION
We have determined that 4-HPR stimulated ceramide in tumor cells by de novo synthesis, as demonstrated by the abrogation of the ceramide increase with inhibitors of de novo synthesis. We have also shown that putative modulators of ceramide metabolism could significantly synergize 4-HPR cytotoxicity in a variety of solid tumor cell lines, with minimal toxicity to normal fibroblasts and myeloid progenitors (marrow GM-CFU). Specifically, combining safingol (L-threo-dihydrosphingosine) with 4-HPR resulted in the following: (a) It caused synergistic, multilog cytotoxicity in cell lines, including p53 mutant cell lines, of neuroblastoma, melanoma, lung cancer, colon cancer, prostate cancer, and pancreatic cancer; (b) it was synergistic in breast cancer cell lines, and (c) it retained cytotoxicity under conditions of physiologic hypoxia. Inhibitors of glucosylceramide synthase and of 1-O-acylceramide synthase, such as tamoxifen and PPMP, could also synergize 4-HPR cytotoxicity, especially in combination with 4-HPR/safingol, most likely by decreasing the conversion of ceramide into glucosylceramides and 1-O-acylceramides in those cell lines in which these ceramide-shunting pathways are highly active. Our preliminary results indicate that 4-HPR/safingol was also highly active against myelogenous and lymphocytic leukemia cell lines (data not shown).
We attempted to demonstrate the extent to which de novo ceramide production contributed to 4-HPR cytotoxicity, both as a single agent and in 4-HPR/safingol, by using inhibitors of de novo ceramide synthesis. L-Cycloserine, an inhibitor of serine palmitoyltransferase, the rate-limiting step of ceramide synthesis, significantly reduced the cytotoxicity of 4-HPR and 4-HPR/ safingol in an MCF-7 cell line derivative. However, L-cycloserine inhibits aminotransferases (53, 54) , decarboxylases (55) , and pyruvate metabolism (56) , in addition to inhibiting serine palmitoyltransferase, and prolonged exposure to L-cycloserine itself caused significant cytotoxicity. Furthermore, L-cycloserine and ␤-chloro-L-alanine cytotoxicity cannot be rescued completely by sphingosine in Chinese hamster ovary cells (57) , further suggesting that these agents significantly perturb cytotoxic, non-sphingolipid-related pathways. Thus, the reduction of 4-HPR and 4-HPR/safingol cytotoxic effects observed with L-cycloserine pretreatment must be interpreted with caution. Paradoxically, an inhibitor of ceramide synthase, fumonisin B 1 , slightly increased the cytotoxicity of 4-HPR in CHLA-90 and SK-N-RA cells. Since inhibition of ceramide synthase results in the accumulation of cytotoxic sphinganine and sphingosine and the depletion of higher order glycosphingolipids, these results should also be interpreted with circumspection. Thus, it is unlikely that L-cycloserine and fumonisin B 1 can be used to definitely demonstrate the contribution made by de novo synthesized ceramide to the cytotoxic effects of 4-HPR and 4-HPR/ safingol. However, our preliminary results with a transfected cell line that overexpresses glucosylceramide synthase (36), which converts ceramide into nontoxic glucosylceramide, indicate that overexpression of glucosylceramide synthase significantly decreases the cytotoxicity of 4-HPR and 4-HPR/safingol (data not shown).
The direct stimulatory effects of 4-HPR on serine palmitoyltransferase and ceramide synthase enzymatic activities in CHLA-90 neuroblastoma cells have been determined and will be reported elsewhere (Cabot MC: unpublished data) . Etoposide has recently been reported (58) to increase de novo ceramide levels via stimulation of serine palmitoyltransferase in Molt-4 leukemia cells. Pretreatment of Molt-4 cells with fumonisin B 1 prevented the etoposide-induced ceramide increase and reduced etoposide-induced cytotoxicity (58) . This result is in contrast to the slight increase in 4-HPR-induced cytotoxicity observed here with fumonisin B 1 pretreatment and may reflect a cell typespecific variation in response to the increase in sphinganine caused by fumonisin B 1 . Taken together, our results and those reported for Molt-4 leukemia (58) support a role for the overproduction of de novo ceramide in the promotion of cell death by both 4-HPR and etoposide.
The subcellular location of the machinery of de novo ceramide synthesis may provide a clue to possible pro-death functions of de novo increases in ceramide. Serine palmitoyltransferase has been enriched from the endoplastic reticulum (41), whereas ceramide synthase activity has been found in the cytosolic aspect of the endoplastic reticulum and is enriched in the mitochondrial fraction (40) . Therefore, it is possible that 4-HPR stimulation of serine palmitoyltransferase activity may increase ceramide levels directly in mitochondria, in addition to increases in ceramide levels in other subcellular compartments. Both short-chain ceramides (59,60) and 4-HPR (61) have been reported to disrupt the mitochondrial respiratory chain between complex II and complex III, resulting in generation of ROS, one reported mechanism of 4-HPR cytotoxicity (8, 9) . Furthermore, sustained mitochondrial electron transport chain decoupling can result in depletion of cellular adenosine triphosphate stores and cell death by necrosis (62, 63) . In this regard, we have demonstrated previously that 4-HPR kills neuroblastoma cells via mixed apoptosis/necrosis (11), perhaps representing death by the process variously termed "necrapoptosis" (62) or "aponecrosis" (64) . In addition, ceramide or its short-chain analogues have been associated with pro-death JNK/SAPK activation (12), dephosphorylation (inactivation) of apoptosis-opposing Bcl-2 via activation of mitochondrial protein phosphatase-2A (PP2A) (15) , and inhibition of the phosphatidylinositol 3-kinase (PI3K)-protein kinase B/Akt1 survival pathway (65, 66) , all of which could potentially contribute to a ceramide-mediated component of 4-HPR cytotoxicity.
The mechanism by which safingol synergizes 4-HPR cytotoxicity is not clear. It may act by inhibiting the regulatory subunit of PKC- (25, 26, 67) . PKC-is activated by ceramide (12), acts to increase NFkappaB (a pro-life transcription factor) (68), may facilitate pro-life p70 S6 kinase activation (69) , and also activates sphingosine kinase (12, 70) . Sphingosine kinase converts sphingosine, a degradation product of ceramide, to sphingosine 1-phosphate, which activates the pro-life extracellular signal-regulated kinase (ERK1/2) cascade (70, 71) . ERK1/2 activation acts to oppose ceramide-stimulated, pro-deathassociated JNK/SAPK activity (70) (71) (72) , and 4-HPR has been reported to increase JNK/SAPK activity (10) . In this regard, our preliminary results indicate that nontoxic doses of safingol (3 M) more rapidly and strongly activate JNK/SAPK in CHLA-90 neuroblastoma cells than does 4-HPR itself (data not shown). We speculate that JNK/SAPK preactivation by safingol may predispose to cell death in a cellular context of de novo ceramide stress induced by 4-HPR. Safingol has also been reported to potentiate arabinofuranosylcytosine-induced apoptosis in HL-60 leukemia cells independently of ceramide-induced JNK/SAPK activation by decreasing the pro-life ERK1/2 cascade activation (73) , perhaps by direct inhibition of PKC-activation of mitogen-activated protein kinase (MAPK) kinase (MEK) (23) .
Whether safingol is synergistic with 4-HPR as the parental L-threo-dihydrosphingosine compound or as its in vivo-acylated, stereochemically variant, ceramide analogue (cer*) is under investigation. It is noteworthy that there was a large accumulation of cer* at minimally toxic doses of safingol (3 M) but that cer* was not glucosylated to glucosylceramide. This finding indicates that the variant stereochemistry of cer* significantly altered its biologic processing compared with native (D-erythro)ceramide. It is possible, in this respect, that cer* retains some but not all of the messenger functions of native ceramide (such as, perhaps, the ability to activate JNK/SAPK). In support of this hypothesis, the activation of ceramide-activated protein phosphatase-1 (PP1) and protein phosphatase-2A (PP2A) by native D-erythro-C 18 -ceramide is stereochemically restricted, with significantly reduced activity induced by the D-threo and L-threo diastereoisomers and the L-erythro enantiomer (74) . Such stereochemical restriction may explain the minimal cytotoxicity of cer* observed when low-dose safingol was used as a single agent.
Current phase I clinical trials of 4-HPR, given orally in 1-week courses, have demonstrated that serum levels of 4-HPR, approximating or exceeding those reported here to achieve multilog cytotoxicity with safingol, are well tolerated clinically (75, 76) . Safingol (at 120 mg/m 2 ) has achieved approximately 3 M plasma levels over 1-hour infusion times without reported toxicity (77) . Our preliminary washout data in vitro indicate that, in some cell lines, safingol need only be co-present for a fraction of the total 4-HPR-exposure period to obtain much of its synergistic cytotoxicity (data not shown). Taken together, these results indicate that animal toxicology studies of continuous infusion of 4-HPR/safingol should be conducted and should be followed by phase I clinical trials as warranted. Future preclinical studies and clinical trials will likely involve combining inhibitors of glucosylceramide synthase, such as tamoxifen, which is tolerated to approximately 7 M plasma levels with pulse oral dosing (78) , and/or inhibitors of 1-O-acylceramide synthase with 4-HPR and 4-HPR/safingol.
Thus, should they be tolerated clinically, combinations of 4-HPR and modulators of ceramide metabolism may form the basis for a novel chemotherapy that is p53 and caspase independent and is active under conditions of reduced oxygen.
